A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final report
European Journal of Cancer2017Vol. 81, pp. 206–225
Citations Over TimeTop 10% of 2017 papers
Astrid Gnekow, David Walker, Daniela Kandels, Susan Picton, Giorgio Perilongo, Jacques Grill, Tore Stokland, Per Eric Sandstrom, Monika Warmuth‐Metz, Torsten Pietsch, Felice Giangaspero, René Schmidt, Andreas Faldum, Denise Kilmartin, Angela De Paoli, Gian Luca De Salvo, Astrid Gnekow, Irene Slavc, Giorgio Perilongo, Sue Picton, David Walker, Tore Stokland, Per Erik Sandstrom, Niels Clausen, Mikko Arola, Ólafur Gísli Jónsson, Ofelia Cruz, Aurora Navajas, Anna Teijeiro, Jacques Grill, C Kalifa, Marie‐Anne Raquin, Joris Verlooy, Volkmar Hans, Torsten Pietsch, Wolfram Scheurlen, Johannes A. Hainfellner, Felice Giangaspero, James W. Ironside, Keith Robson, Kari Skullerud, David Scheie, Nn Nn, Marie-Madeleine Ruchoux, Anne Jouvet, Dominique Figarella‐Branger, Arielle Lellouch-Toubiana, Monika Warmuth‐Metz, Daniela Prayer, Milena Calderone, Tim Jaspan, S. J. Bakke, Eli Abraham Vázquez, D. Couanet, Rolf D. Kortmann, Karin Diekmann, Giovanni Scarzello, Roger Taylor, Knut Lote, J. Giralt, C. Carrié, Jean Louis Habrand, Niels Soerensen, Thomas Czech, Paul Chumas, Bengt Gustavson, Michel Zérah, Bettina Wabbels, Maria Luisa Pinello, Alistair R. Fielder, Ian Simmons, Terje Christoffersen, Gabriele Calaminus, Knut Brockmann, Ronald Straeter, Friedrich Ebinger, Pablo Hernáiz Driever, Herwig Lackner, Colin Kennedy, Adam Glaser, Bo Strömberg, José M. Indiano, C Rodary, Éric Bouffet, Didier Frappaz, Andreas Faldum, Angela Emser, Gian Luca De Salvo, Suzanne Stephens, David Machin, Marie‐Cécile Le Deley, Thore Egeland, Carolyn Freemann, Martin Schrappe, Richard Sposto
Abstract
The addition of etoposide to VC did not improve PFS or OS. High non-progression rates at 24 weeks justify retaining VC as standard first-line therapy. Infants with diencephalic syndrome and early progression need new treatments to be tested. Future trials should use neurological/visual and toxicity outcomes and be designed to discriminate between the impact on disease outcomes of 'duration of therapy' and 'age at stopping therapy'.
Related Papers
- → Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non–small-cell lung cancer: A randomized trial(2001)52 cited
- → Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.(1993)15 cited
- [Phase II study with etoposide/vincristine in small cell bronchial cancer (extensive disease)].(1990)
- → Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial(2002)